Clearmind Medicine Raises $2.185M in Direct Offering
Ticker: CMND · Form: 6-K · Filed: Nov 19, 2025 · CIK: 1892500
Sentiment: neutral
Topics: offering, capital-raise, shares
TL;DR
Clearmind Medicine just sold 10.9M shares at $0.20 for $2.185M. Expecting cash infusion.
AI Summary
On November 19, 2025, Clearmind Medicine Inc. entered into a securities purchase agreement to sell 10,925,000 common shares at $0.20 per share in a registered direct offering. This offering is expected to raise approximately $2.185 million before deducting offering expenses.
Why It Matters
This capital raise provides Clearmind Medicine with funds to advance its operations and potentially its drug development pipeline.
Risk Assessment
Risk Level: medium — The company is conducting a registered direct offering, which can dilute existing shareholders and may indicate a need for immediate capital.
Key Numbers
- $2.185M — Gross Proceeds (Funds raised from the registered direct offering.)
- 10,925,000 — Shares Sold (Number of common shares sold in the offering.)
- $0.20 — Price Per Share (The price at which each common share was sold.)
Key Players & Entities
- Clearmind Medicine Inc. (company) — Filer and issuer of securities
- November 19, 2025 (date) — Date of securities purchase agreement and offering
- 10,925,000 (dollar_amount) — Number of common shares sold in the offering
- $0.20 (dollar_amount) — Purchase price per common share
- $2.185 million (dollar_amount) — Gross proceeds from the offering
FAQ
What is the total gross amount Clearmind Medicine expects to raise from this offering?
Clearmind Medicine expects to raise approximately $2.185 million in gross proceeds from the sale of 10,925,000 common shares at $0.20 per share.
When was the securities purchase agreement for this offering entered into?
The securities purchase agreement was entered into on November 19, 2025.
How many common shares are being sold in this registered direct offering?
10,925,000 common shares are being sold in the offering.
What is the price per common share in this offering?
The purchase price per common share is $0.20.
What type of offering is Clearmind Medicine conducting?
Clearmind Medicine is conducting a registered direct offering.
Filing Stats: 778 words · 3 min read · ~3 pages · Grade level 13.1 · Accepted 2025-11-19 06:09:03
Key Financial Figures
- $0.20 — Offering”) at a purchase price of $0.20 per Common Share. The Offering is expe
- $2.185 million — ompany are expected to be approximately $2.185 million. The Company expects to use the net pro
Filing Documents
- ea0266289-6k_clearmind.htm (6-K) — 17KB
- ea026628901ex5-1_clearmind.htm (EX-5.1) — 21KB
- ea026628901ex10-1_clearmind.htm (EX-10.1) — 187KB
- ex5-1_001.jpg (GRAPHIC) — 3KB
- ex5-1_002.jpg (GRAPHIC) — 1KB
- 0001213900-25-112331.txt ( ) — 232KB
Forward Looking Statements
Forward Looking Statements This Report of on Form 6-K contains statements which constitute forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. These forward looking statements are based upon the Company’s present intent, beliefs or expectations, but forward looking statements are not guaranteed to occur and may not occur for various reasons, including some reasons which are beyond the Company’s control. For example, this Report states that the Offering is expected to close on or about November 20, 2025. In fact, the closing of the Offering is subject to various conditions and contingencies as are customary in securities purchase agreements in the United States. If these conditions are not satisfied or the specified contingencies do not occur, this Offering may not close. For this reason, among others, you should not place undue reliance upon the Company’s forward looking statements. Except as required by law, the Company undertakes no obligation to revise or update any forward looking statements in order to reflect any event or circumstance that may arise after the date of this Report on Form 6-K. 1 EXHIBIT INDEX Exhibit No. 5.1 Opinion of Daniel N. Bloch, Canadian counsel to the Company 10.1 Form of Securities Purchase Agreement 23.1 Consent of Daniel N. Bloch (included in Exhibit 5.1) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Clearmind Medicine, Inc. (Registrant) Date: November 19, 2025 By: /s/ Adi Zuloff-Shani Name: Adi Zuloff-Shani Title: Chief Executive Officer 3